Strateos Valuation, Funding & Investors
Strateos is valued at $37M as of November 2016.
Last Strateos valuation
$37M
Series A · Nov 2016
Last Strateos funding round
$56M
Series B · Jun 2021
Cumulative funding Strateos raised
$103M
across 8 funding rounds
Key investors in Strateos
DCVC
Lux Capital
AME Cloud Ventures
Y Combinator
Silicon Valley Bank
Dolby Family Ventures
About Strateos
Strateos is a Newark-headquartered cloud laboratory platform automating chemistry, biology, and tissue analysis for drug discovery. Formed in 2020 from the merger of Transcriptic founded in 2012 and 3Scan, it integrates robotics, imaging software, and analytics to serve pharmaceutical partners, enabling remote experimentation and 3D tissue mapping for faster candidate identification.
Founded
2012
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Subscription, Usage-based
Valuation
$37M (Nov 2016)
Strateos Valuation
Strateos is currently valued at $37M, based on its Series A in November 2016.
The $13M round was led by DCVC, with participation from Wuxi AppTec, Digital Science, AME Cloud Ventures and Holtzbrinck Digital.
Strateos valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Nov 2016 | Series A | $37M |
Strateos Funding History
Strateos has raised a total of $103M across 8 funding rounds.
Strateos' first fundraising round was a $3M seed round in February 2014. The most recent completed round was a $56M Series B in June 2021.
Strateos funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2021 | Series B | DCVC (lead); Lux Capital (lead); Harmonix Fund; Castor Ventures; Alumni Ventures; AME; Veris Residential; Eli Lilly; StreShi; Dolby Family Ventures; Ally Bridge Group; Black Diamond Ventures | $56M | - | Strateos, formerly Transcriptic, is a Menlo Park, CA-based company developing remote access laboratories and lab control software for life science research, offering a 'SmartLab of the Future' platform with automation. The company operates in the biotech sector, focusing on computational and robotic solutions for drug discovery and research automation. On June 8, 2021, it closed a $56 million (or $56.1 million) Series B funding round led by DCVC and Lux Capital, with participation from Ally Bridge Group, Alumni Ventures, Black Diamond Ventures, Castor Ventures, Dolby Family Ventures, Eli Lilly and Company, Harmonix Fund, and others. The funds aim to accelerate rollout and expansion of its next-generation smart lab solutions providing direct access to automation. Prior to this round, Strateos had raised additional amounts in earlier rounds including Seed, Series A stages, bringing total funding to approximately $98.5 million across 10 rounds by 2022. DCVC participated in multiple prior rounds since 2014, including Seed, Series A (2015), Series A - II (2016), and Series A - III (2019). A later Series B - II round occurred on December 13, 2022. |
| Dec 2020 | Series B | Black Diamond Ventures | $4M | - | - |
| Jul 2019 | Undisclosed stage | Lux Capital; BGS Venture; Dolby Family Ventures; DCVC | $17M | - | - |
| Nov 2016 | Series A | DCVC (lead); Wuxi AppTec; Digital Science; AME Cloud Ventures; Holtzbrinck Digital | $13M | $37M | Strateos (formerly Transcriptic) operates a cloud lab platform enabling remote experiment design, execution, and analysis using automation, robotics, and data tools to accelerate life science research and drug discovery. The company received funding in November 2016 with a reported valuation of $36.6M. DCVC participated as a lead investor alongside AME Cloud Ventures, Digital Science, Holtzbrinck Digital, and Wuxi AppTec. Strateos continued raising capital, achieving a total of $98.52M across eight rounds by 2022, including a $56M Series B in June 2021 led by DCVC and Lux Capital with participation from Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, and others. |
| Feb 2015 | Series A | DCVC (lead); Y Combinator; AME Cloud Ventures; IA Ventures; Holtzbrinck Digital; Silicon Valley Bank; UpHonest Capital; Paul Buchheit; 500 Global; MITS Fund | $9M | - | Strateos, originally known as Transcriptic, raised an $8.5 million Series A funding round in 2015 led by DCVC, with participation from investors including 500 Global, AME Cloud Ventures, Holtzbrinck Digital, IA Ventures, MITS Fund, Paul Buchheit, Silicon Valley Bank, UpHonest Capital, Wei Guo, and Y Combinator. The company pioneered remote access laboratories and lab control software for life science research, later evolving into the SmartLab Platform to integrate automation, data generation, and AI for accelerating pharmaceutical and synthetic biology R&D. In 2019, Transcriptic merged with 3Scan to form Strateos, enhancing its capabilities in robotic, cloud-based lab platforms targeting drug discovery and development. Subsequent funding included a $13 million venture round in October 2016 and a $17 million venture round in June 2019. The company raised a $56.1 million Series B in June 2021, co-led by DCVC and Lux Capital, with investors such as Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Castor Ventures, and Mack & Co. This brought total funding to over $98 million across multiple rounds. Strateos directed later capital toward expanding its SmartLab platform, adding R&D tools, and partnering with entities like Eli Lilly for life sciences studios. |
| Dec 2014 | Seed | Y Combinator; Lux Capital | $100K | - | - |
| Jul 2014 | Seed | Silicon Valley Bank | $2M | - | - |
| Feb 2014 | Seed | GV; AME Cloud Ventures; IA Ventures; DCVC | $3M | - | - |
Who has invested in Strateos?
25 investors have backed Strateos across its funding rounds, including DCVC, Lux Capital, AME Cloud Ventures, Y Combinator, Silicon Valley Bank and Dolby Family Ventures.
Lead investors include DCVC and Lux Capital.
Strateos Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| United States | 5 | Lead | Feb 2014 | |
| New York City, NY | 3 | Lead | Dec 2014 | |
| San Francisco, CA | 3 | Participant | Feb 2014 | |
| San Francisco, CA | 2 | Participant | Dec 2014 | |
| United States | 2 | Participant | Feb 2014 | |
 Munich | 2 | Participant | Feb 2015 | |
| San Francisco, CA | 2 | Participant | Jul 2019 | |
| San Jose, CA | 2 | Participant | Jul 2014 | |
| Los Angeles, CA | 2 | Participant | Dec 2020 | |
 Shanghai | 1 | Participant | Nov 2016 | |
| San Francisco, CA | 1 | Participant | Feb 2014 | |
| La Quinta, CA | 1 | Participant | Jun 2021 | |
| Boston, MA | 1 | Participant | Jun 2021 | |
This data is available for Pro users. Sign up to see all 25 Strateos investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Strateos
Strateos has acquired 1 company to date.
Last acquisition by Strateos was on June 3rd 2019. Strateos acquired 3Scan for undisclosed valuation.
Latest Acquisitions by Strateos
| Description | 3Scan is a San Francisco-headquartered biotech company founded in 2011 developing robotic microscopy for 3D tissue imaging to analyze diseases like cancer and Alzheimer's. Its Knife-Edge Scanning Microscopy processes whole organs into volumetric datasets for quantitative pathology. 3Scan partners with pharmaceutical firms for drug discovery screening. |
| HQ Country | |
| HQ City | - |
| Deal Date | 3 Jun 2019 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Strateos acquisitions and their M&A valuation multiples. Start Free Trial | |
Strateos Competitors
Strateos competitors include listed companies like LSL Pharma Group and WDB coco, and private ones like Mytide Therapeutics, TSD Life Sciences, Mosaic Biosciences and Heligenics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Boston, MA | Private | - | - | $35M | - | |
 Seoul | Private | - | - | $40M | - | |
 Canada | Publicly listed | $21M | $2M | $29M | - | |
| Boulder, CO | Private | - | - | $26M | - | |
| Las Vegas, NV | Private | - | - | $38M | - | |
 Japan | Publicly listed | $31M | $7M | $40M | 0.5x |
Strateos Public Comps
Strateos is still privately-owned, but its public comps include WDB coco, J. Molner, Bio-Works Technologies, Genoway, Mabion, Cryosite, Drone Volt, AnteoTech, Biohit and Softing.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $31M | $7M | 0.5x | 0.5x | 2.2x | - | |||
| $1M | $1M | 26.2x | - | 34.4x | - | |||
| $6M | ($2M) | 4.8x | - | (17.5x) | - | |||
| $24M | $6M | 1.7x | 1.6x | 7.3x | 9.8x | |||
| $4M | ($14M) | 9.7x | 6.2x | (2.9x) | (5.0x) | |||
| $12M | $3M | 3.7x | - | 14.6x | - | |||
| $10M | ($11M) | 3.3x | 2.4x | (2.9x) | (8.7x) | |||
| $689K | ($4M) | 51.3x | 15.8x | (8.8x) | (19.2x) | |||
This data is available for Pro users. Sign up to see all Strateos competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Strateos
| When was Strateos founded? | Strateos was founded in 2012. |
| Where is Strateos headquartered? | Strateos is headquartered in San Francisco, CA, United States. |
| Is Strateos publicly listed? | No, Strateos is a private, VC-backed company. |
| What is Strateos' valuation? | Strateos was last valued at $37M in its Series A in November 2016. |
| How much funding has Strateos raised? | Strateos has raised $103M across 8 funding rounds. |
| What was Strateos' last funding round? | Strateos' last funding round was a $56M Series B in June 2021, led by DCVC and Lux Capital. |
| Who are Strateos' investors? | Strateos' investors include DCVC, Lux Capital, AME Cloud Ventures, Y Combinator, IA Ventures, Holtzbrinck Digital, Dolby Family Ventures, Silicon Valley Bank, Black Diamond Ventures, Wuxi AppTec and 15 others. |
| Which companies are comparable to Strateos? | Companies comparable to Strateos include Mytide Therapeutics, TSD Life Sciences, LSL Pharma Group, Mosaic Biosciences, Heligenics and WDB coco. |
| How many companies has Strateos acquired? | Strateos has acquired 1 company, including 3Scan. |
See companies similar to Strateos
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.